Vitrotest is an experienced manufacturer and supplier of enzyme immunoassay kits and raw materials for immunoassays. For more than 20 years, the company has been constantly developing new high-tech products and introducing innovative solutions in the field of laboratory diagnostics.
Since our formation, we have worked on a significant number of ELISA tests for the diagnosis of infectious diseases caused by viruses, bacteria, and parasites, adding to them the diagnosis of allergic conditions and cancer.
During the supply of products, the company was able to form a friendly partnership relationship with many diagnostic laboratories.
Recently, Vitrotest has concentrated on the development of new original products and affordable raw materials for biotechnological production.
We develop and manufacture native and recombinant antigens, monoclonal antibodies, and synthetic controls which are used as the key components of laboratory tests. Most of the components we have created have stood the test of time as part of our finished diagnostic products.
You can find the reagent you need in the appropriate section or by using the product finder.
MEDICA 2024
From 11 to 14 November 2024 MEDICA will once again bring together international medical experts from more than 70 countries in Düsseldorf, Germany. Vitrotest Group will once again present high-quality and innovative products at the exhibition. Vitrotest® consistently strives to push the boundaries of scientific research and development in the field of diagnostics. The exhibition will serve [...]
Recombinant proteins p24
Vitrotest is proud to announce the launch of its latest innovation, HIV -1 Recombinant Proteins p24, designed to enhance HIV-1 Ab detection efforts. These advanced proteins contain immunodominant regions specific to HIV-1, making it highly effective for detecting antibodies to the virus in clinical and research settings. With its precision and reliability, p24 recombinant proteins promise to [...]
Monoclonal antibodies to HE4
Company Vitrotest has introduced new monoclonal antibodies designed to specifically detect tumor marker HE4 (human epididymis protein 4), a crucial indicator in ovarian cancer. These antibodies are optimized for immunoenzyme assays, enhancing the accuracy of cancer diagnostics by precisely binding to this marker. This product represents a key advancement in diagnostic tools, enabling more reliable and targeted [...]